Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

Phase 4 Completed 47 enrolled Young-Hak Kim, MD, PhD

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate effectiveness of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy after Percutaneous Coronary Intervention.

Timeline

Start: 2015-01-21
Primary completion: 2018-12-01
Completion: 2019-01-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ALBIS	Unknown	—	Oral

Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

Summary

Timeline

Drugs

Indications